136 patents
Page 6 of 7
Utility
Compositions for modulating C9ORF72 expression
26 Oct 20
Disclosed herein are compositions and methods for reducing expression of C9ORF72 mRNA and protein in an animal.
Frank Rigo
Filed: 16 Oct 18
Utility
Compositions for modulating expression of C9ORF72 antisense transcript
5 Oct 20
Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors.
Frank Rigo
Filed: 5 Jan 16
Utility
Compositions and methods for modulating growth hormone receptor expression
5 Oct 20
The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Sanjay Bhanot, Susan M. Freier, Huynh-Hoa Bui
Filed: 23 Jul 19
Utility
Modulation of Factor 11 expression
14 Sep 20
Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof.
Susan M. Freier
Filed: 11 Feb 19
Utility
Modulators of PNPLA3 expression
14 Sep 20
The present embodiments provide methods, compounds, and compositions useful for inhibiting PNPLA3 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PNPLA3.
Susan M. Freier, Huynh-Hoa Bui
Filed: 17 Sep 19
Utility
Method for synthesis of reactive conjugate clusters
24 Aug 20
Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods.
Michael T. Migawa, Jinghua Yu, W. Brad Wan, Sayten P. Patel, Guillermo Vasquez, Garth A. Kinberger, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 6 Sep 18
Utility
Compounds and methods for detecting oligonucleotides
24 Aug 20
The present invention provides methods of detecting and/or quantitating a target oligonucleotide in a biological sample.
Sarah Greenlee, Zhengrong Yu, Thazha P. Prakash, John E. Matson
Filed: 9 Nov 14
Utility
Methods of predicting toxicity
17 Aug 20
Described herein are compounds useful for the treatment and investigation of diseases, methods for the prediction of in vivo toxicity of compounds useful for the treatment and investigation of diseases, and methods of discovering and identifying compounds useful for the treatment and investigation of diseases that have reduced in vivo toxicity.
Sebastien Burel
Filed: 24 Jul 17
Utility
Compositions and their uses directed to huntingtin
10 Aug 20
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal.
Gene Hung, C. Frank Bennett, Janet M. Leeds, Susan M. Freier
Filed: 4 Oct 17
Utility
Compositions and methods for modulating TTR expression
15 Jun 20
Provided herein are oligomeric compounds with conjugate groups.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 24 Aug 17
Utility
5′ modified nucleosides and oligomeric compounds prepared therefrom
8 Jun 20
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 27 Jul 15
Utility
Compositions and their uses directed to huntingtin
18 May 20
Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal.
Susan M. Freier
Filed: 6 Feb 18
Utility
Method for solution phase detritylation of oligomeric compounds
13 Apr 20
Provided herein are methods for the synthesis of oligomeric compounds wherein removal of the 5′-terminal trityl group is performed at reduced temperature and lower pH relative to standard methods.
Dana Chreng
Filed: 26 Jul 17
Utility
Cancer treatment
13 Apr 20
In certain embodiments, methods, compounds, and compositions for treating B-cell lymphoma or hepatocellular carcinoma by inhibiting expression of STAT3 mRNA or protein in an animal are provided herein.
Stanley T. Crooke, Mason Yamashita
Filed: 26 Nov 17
Utility
Modulation of huntingtin expression
13 Apr 20
Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal.
Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
Filed: 7 Feb 19
Utility
Compositions and methods for modulation nucleic acids through nonsense mediated decay
16 Mar 20
Disclosed herein are compounds, compositions and methods for modulating the amount or activity of a target nucleic acid.
Amanda Ward, Frank Rigo
Filed: 20 Apr 14
Utility
Methods for monitoring C9ORF72 expression
2 Mar 20
Disclosed herein are methods for monitoring expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors.
C. Frank Bennett, Susan M. Freier, Jeffrey D. Rothstein, Christopher Donnelly, Rita G. Sattler
Filed: 14 Oct 13
Utility
Modulation of DYRK1B expression
2 Mar 20
Provided herein are methods, compounds, and compositions for reducing expression of DYRKIB in an animal.
Brett P. Monia, Shuling Guo, Susan F. Murray
Filed: 15 Mar 17
Utility
Conjugated antisense compounds and their use
24 Feb 20
Provided herein are oligomeric compounds with conjugate groups.
Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
Filed: 20 May 15
Utility
Modulating apolipoprotein (a) expression
10 Feb 20
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)].
Nicholas J. Viney, Richard S. Geary, Yanfeng Wang, Zhengrong Yu
Filed: 6 Nov 16